Protagonist Therapeutics (PTGX) News Today $65.08 -0.39 (-0.59%) As of 03:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PTGX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Protagonist Therapeutics' (PTGX) Buy Rating Reiterated at HC WainwrightOctober 8 at 8:26 AM | marketbeat.comProtagonist Therapeutics price target raised to $74 from $62 at Clear StreetOctober 7 at 7:15 PM | msn.comProtagonist Therapeutics (PTGX): Evaluating Valuation After a 65% Year-to-Date Share Price SurgeOctober 7 at 2:14 PM | finance.yahoo.comProtagonist Therapeutics, Inc. $PTGX Shares Bought by State of Alaska Department of RevenueOctober 3, 2025 | marketbeat.com14,339 Shares in Protagonist Therapeutics, Inc. $PTGX Acquired by Precision Wealth Strategies LLCOctober 2, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Shares Down 5.1% - What's Next?September 29, 2025 | marketbeat.com7,530 Shares in Protagonist Therapeutics, Inc. $PTGX Acquired by Palumbo Wealth Management LLCSeptember 25, 2025 | marketbeat.comAssenagon Asset Management S.A. Increases Stock Position in Protagonist Therapeutics, Inc. $PTGXSeptember 25, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Director Sells $257,000.00 in StockSeptember 24, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Reaches New 12-Month High - Should You Buy?September 24, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Rating of "Buy" from AnalystsSeptember 22, 2025 | marketbeat.comExchange Traded Concepts LLC Purchases 19,999 Shares of Protagonist Therapeutics, Inc. $PTGXSeptember 21, 2025 | marketbeat.comVoya Investment Management LLC Cuts Stock Position in Protagonist Therapeutics, Inc. $PTGXSeptember 21, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Reaches New 12-Month High - What's Next?September 19, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Upgraded by Barclays to Strong-Buy RatingSeptember 19, 2025 | marketbeat.comStrs Ohio Invests $919,000 in Protagonist Therapeutics, Inc. $PTGXSeptember 19, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Given Buy Rating at HC WainwrightSeptember 18, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Now Covered by BarclaysSeptember 18, 2025 | marketbeat.comBarclays Initiates Coverage of Protagonist Therapeutics (PTGX) with Overweight RecommendationSeptember 17, 2025 | msn.comDemystifying Protagonist Therapeutics: Insights From 4 Analyst ReviewsSeptember 17, 2025 | benzinga.comProtagonist Therapeutics, Inc. (PTGX): A Bull Case TheorySeptember 17, 2025 | msn.comProtagonist Therapeutics, Inc. (PTGX): A Bull Case Theory September 17, 2025 | insidermonkey.comBarclays backs biotech with fresh calls on oncology and immunology stocksSeptember 17, 2025 | investing.comProtagonist Therapeutics initiated with an Overweight at BarclaysSeptember 16, 2025 | msn.comProtagonist Therapeutics: Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025September 16, 2025 | finanznachrichten.deWhat is Leerink Partnrs' Estimate for PTGX Q3 Earnings?September 16, 2025 | marketbeat.comExploring High Growth Tech Stocks in the US Market September 2025September 15, 2025 | finance.yahoo.comProtagonist Therapeutics (NASDAQ:PTGX) Upgraded at Leerink PartnrsSeptember 15, 2025 | marketbeat.comProtagonist Therapeutics, Inc. $PTGX Shares Acquired by Inspire Investing LLCSeptember 15, 2025 | marketbeat.comLeerink Partners Initiates Coverage on Protagonist Therapeutics (NASDAQ:PTGX)September 14, 2025 | marketbeat.comFocus Partners Wealth Boosts Holdings in Protagonist Therapeutics, Inc. $PTGXSeptember 14, 2025 | marketbeat.comEmpowered Funds LLC Takes $4.96 Million Position in Protagonist Therapeutics, Inc. $PTGXSeptember 14, 2025 | marketbeat.comProtagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines AgencySeptember 13, 2025 | finance.yahoo.comFred Alger Management LLC Invests $362,000 in Protagonist Therapeutics, Inc. $PTGXSeptember 13, 2025 | marketbeat.comProtagonist Therapeutics initiated with an Outperform at LeerinkSeptember 12, 2025 | msn.comLeerink Partners Initiates Coverage of Protagonist Therapeutics (PTGX) with Outperform RecommendationSeptember 12, 2025 | msn.comGreat Lakes Advisors LLC Acquires 90,371 Shares of Protagonist Therapeutics, Inc. $PTGXSeptember 12, 2025 | marketbeat.comProtagonist Therapeutics announces icotrokinra application submitted to EMASeptember 11, 2025 | msn.comWoodline Partners LP Purchases 315,372 Shares of Protagonist Therapeutics, Inc. $PTGXSeptember 11, 2025 | marketbeat.com39,969 Shares in Protagonist Therapeutics, Inc. $PTGX Bought by Axiom Investors LLC DESeptember 11, 2025 | marketbeat.com20,765 Shares in Protagonist Therapeutics, Inc. $PTGX Bought by Coppell Advisory Solutions LLCSeptember 11, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (PTGX) Presents At H.C. Wainwright 27th Annual Global Investment Conference TranscriptSeptember 11, 2025 | seekingalpha.comProtagonist Therapeutics (NASDAQ:PTGX) Trading Down 8.7% - What's Next?September 10, 2025 | marketbeat.comScientech Research LLC Grows Position in Protagonist Therapeutics, Inc. $PTGXSeptember 10, 2025 | marketbeat.comState of Wyoming Reduces Position in Protagonist Therapeutics, Inc. $PTGXSeptember 10, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Invests $16.61 Million in Protagonist Therapeutics, Inc. $PTGXSeptember 8, 2025 | marketbeat.comNew Vernon Capital Holdings II LLC Has $16.83 Million Stock Holdings in Protagonist Therapeutics, Inc. $PTGXSeptember 7, 2025 | marketbeat.comEFG Asset Management North America Corp. Purchases Shares of 71,134 Protagonist Therapeutics, Inc. $PTGXSeptember 6, 2025 | marketbeat.comCheckpoint Capital L.P. Takes Position in Protagonist Therapeutics, Inc. $PTGXSeptember 6, 2025 | marketbeat.comProtagonist Therapeutics, Inc. $PTGX is BVF Inc. IL's 6th Largest PositionSeptember 5, 2025 | marketbeat.com Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PTGX Media Mentions By Week PTGX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PTGX News Sentiment▼1.380.56▲Average Medical News Sentiment PTGX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PTGX Articles This Week▼67▲PTGX Articles Average Week Get the Latest News and Ratings for PTGX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Protagonist Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Summit Therapeutics News Dr. Reddy's Laboratories News Ascendis Pharma A/S News Viatris News Roivant Sciences News Elanco Animal Health News QIAGEN News BridgeBio Pharma News Moderna News Verona Pharma PLC American Depositary Share News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PTGX) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gol...StockEarnings | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredAn Early Move On The Next Shift In CoinLitecoin is already processing 500,000+ daily transactions, integrated with PayPal and Revolut, and now one fi...Market Tactic | Sponsored"I'm risking my reputation on this"If I'm right about what's coming, this could be the most important book you'll read this yearCrypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
